Pi Health
Overview
Pi Health Sciences, a subsidiary of PI Industries, provides leading research services across the pharmaceutical value chain, with a focus on contract research, development, and manufacturing. Headquartered in India, Pi Health Science offers solutions spanning pharmaceuticals, key starting materials (KSM), and active pharmaceutical ingredients (API). Its expertise includes flow chemistry, chemical engineering, and biocatalysis, aimed at driving innovation and fostering partnerships across Europe, the USA, and Asia.
Recent Developments
- October 2024: Pi Health Sciences presented their innovations and industry-leading flow chemistry processes at CPHI Milan 2024. The company showcased its capabilities in medicinal chemistry and biocatalysis.
- September 2024: The announcement of Dr. Mahavir Prashad joining as Chief Development Officer to enhance the company’s research and development progress.
- June 2023: Acquisition of Solis Pharmaceuticals, a drug manufacturer based in Hyderabad, India.
- Throughout 2023: Pi Health Sciences conducted three acquisitions in Genomics and Life Sciences Platforms and Tools sectors within India and the UK, aiming to expand their foothold and capabilities in the life sciences industry.
Company Information
| Attribute | Information |
|---|---|
| Founding Date | Not available |
| Headquarters | India |
| Founders | Not available |
| Revenue | Not disclosed |
| Profits | Not disclosed |
| Key Investors | PI Industries |
| Industry | Research Services |
| Number of Employees | 501-1,000 |
Early History
Pi Health Sciences began its journey focusing on creating a formidable footprint in the life sciences sector. As a division under PI Industries, which has a legacy of over 75 years, Pi Health leveraged its parent company's extensive experience in complex chemistry and global compliance standards. Initially, the company focused on offering integrated solutions that align with global innovation standards.
Company Profile and Achievements
- Pi Health Sciences operates as a fully-owned subsidiary of PI Industries, leading in providing CRO, CDMO, KSM, and API solutions.
- It emphasizes innovation-driven solutions across the pharmaceutical and biotechnology fields.
- The firm has broadened its services to include APIs for complex drug synthesis and has significantly invested in R&D.
- Pi Health Sciences has partnered with numerous global innovators, consistently expanding its services through strategic acquisitions and collaborations.
- Flow chemistry and biologics have been key areas of innovation.
Current Operations and Market Position
Pi Health Sciences continues to assert its presence in the competitive pharmaceutical research and development market by offering comprehensive end-to-end solutions. As a CDMO, it provides highly customized services tailored to specific client needs. Currently, it focuses on expanding its market share in Europe and North America while tapping into emerging industries such as biologics and biocatalysis.
Conclusion
Pi Health Sciences demonstrates dynamic growth and strategic maneuvers within the pharmaceutical research services industry. By leveraging cutting-edge chemistry and partnership with global innovators, it remains a significant player poised for future expansion. The innovative drive positions the company favorably for continuing its pivotal role in the life sciences sector, focusing on sustainable and integrated solutions.